drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01263 | DB09082 | 859 | 659 | [
"DDInter1494",
"DDInter1934"
] | Posaconazole | Vilanterol | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
859,
24,
659
]
],
[
[
859,
63,
1220
],
[
1220,
23,
659
]
],
[
[
859,
24,
423
],
[
423,
23,
659
]
],
[
[
859,
64,
175
],
[
175,
2... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Ciclesonide a... |
DB01182 | DB09074 | 371 | 1,362 | [
"DDInter1534",
"DDInter1327"
] | Propafenone | Olaparib | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
371,
24,
1362
]
],
[
[
371,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
371,
63,
2
],
[
2,
24,
1362
]
],
[
[
371,
24,
1619
],
[
1619,
... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
... | Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Alosetron and Alose... |
DB10429 | DB15091 | 200 | 676 | [
"DDInter282",
"DDInter1901"
] | Candida albicans | Upadacitinib | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
200,
24,
676
]
],
[
[
200,
63,
1184
],
[
1184,
25,
676
]
],
[
[
200,
24,
76
],
[
76,
25,
676
]
],
[
[
200,
63,
1184
],
[
1184,
2... | [
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
... | Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab and Mogamuli... |
DB00531 | DB11817 | 450 | 1,259 | [
"DDInter456",
"DDInter165"
] | Cyclophosphamide | Baricitinib | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
450,
25,
1259
]
],
[
[
450,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
450,
24,
949
],
[
949,
24,
1259
]
],
[
[
450,
62,
831
],
[
831,
... | [
[
[
"Cyclophosphamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium ... |
DB00390 | DB00782 | 1,252 | 1,123 | [
"DDInter554",
"DDInter1535"
] | Digoxin | Propantheline | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Minor | 0 | [
[
[
1252,
23,
1123
]
],
[
[
1252,
18,
1954
],
[
1954,
57,
1123
]
],
[
[
1252,
21,
28762
],
[
28762,
60,
1123
]
],
[
[
1252,
23,
1192
],
[
... | [
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propantheline"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"COG2"
],
[
"COG2",
"{u} (Gene) is downregulated by {v} (Comp... | Digoxin (Compound) downregulates COG2 (Gene) and COG2 (Gene) is downregulated by Propantheline (Compound)
Digoxin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Propantheline (Compound)
Digoxin may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium... |
DB00013 | DB00991 | 1,255 | 97 | [
"DDInter1905",
"DDInter1358"
] | Urokinase | Oxaprozin | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Moderate | 1 | [
[
[
1255,
24,
97
]
],
[
[
1255,
24,
1274
],
[
1274,
24,
97
]
],
[
[
1255,
25,
936
],
[
936,
63,
97
]
],
[
[
1255,
64,
1578
],
[
1578,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Urokinase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a... |
DB01097 | DB05773 | 1,377 | 1,047 | [
"DDInter1033",
"DDInter1848"
] | Leflunomide | Trastuzumab emtansine | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Major | 2 | [
[
[
1377,
25,
1047
]
],
[
[
1377,
64,
848
],
[
848,
24,
1047
]
],
[
[
1377,
25,
375
],
[
375,
63,
1047
]
],
[
[
1377,
63,
458
],
[
458,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
... | Leflunomide may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Leflunomide may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pego... |
DB00529 | DB01276 | 789 | 123 | [
"DDInter779",
"DDInter706"
] | Foscarnet | Exenatide | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
789,
24,
123
]
],
[
[
789,
24,
708
],
[
708,
63,
123
]
],
[
[
789,
24,
1573
],
[
1573,
24,
123
]
],
[
[
789,
63,
251
],
[
251,
2... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Pre... |
DB00697 | DB09488 | 876 | 103 | [
"DDInter1821",
"DDInter23"
] | Tizanidine | Acrivastine | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
876,
24,
103
]
],
[
[
876,
63,
85
],
[
85,
24,
103
]
],
[
[
876,
24,
1264
],
[
1264,
24,
103
]
],
[
[
876,
40,
1617
],
[
1617,
2... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
... | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may ... |
DB00176 | DB00443 | 529 | 251 | [
"DDInter770",
"DDInter195"
] | Fluvoxamine | Betamethasone | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
529,
24,
251
]
],
[
[
529,
24,
617
],
[
617,
40,
251
]
],
[
[
529,
24,
870
],
[
870,
1,
251
]
],
[
[
529,
6,
8374
],
[
8374,
45,... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Betamethasone (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betamet... |
DB00277 | DB11791 | 1,031 | 785 | [
"DDInter1791",
"DDInter287"
] | Theophylline | Capmatinib | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
1031,
24,
785
]
],
[
[
1031,
63,
837
],
[
837,
23,
785
]
],
[
[
1031,
23,
1215
],
[
1215,
23,
785
]
],
[
[
1031,
24,
379
],
[
379,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Theophylline may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and ... |
DB04948 | DB11113 | 1,084 | 657 | [
"DDInter1083",
"DDInter307"
] | Lofexidine | Castor oil | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1084,
24,
657
]
],
[
[
1084,
24,
927
],
[
927,
63,
657
]
],
[
[
1084,
24,
1491
],
[
1491,
24,
657
]
],
[
[
1084,
25,
985
],
[
985,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Mid... |
DB00912 | DB00999 | 473 | 504 | [
"DDInter1581",
"DDInter883"
] | Repaglinide | Hydrochlorothiazide | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Moderate | 1 | [
[
[
473,
24,
504
]
],
[
[
473,
24,
1326
],
[
1326,
40,
504
]
],
[
[
473,
24,
178
],
[
178,
1,
504
]
],
[
[
473,
63,
323
],
[
323,
40... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles H... |
DB06603 | DB14444 | 39 | 151 | [
"DDInter1387",
"DDInter924"
] | Panobinostat | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
39,
24,
151
]
],
[
[
39,
63,
66
],
[
66,
24,
151
]
],
[
[
39,
25,
1619
],
[
1619,
24,
151
]
],
[
[
39,
24,
850
],
[
850,
24,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that cou... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Panobinostat may lead to a major li... |
DB08826 | DB14962 | 1,292 | 1,363 | [
"DDInter489",
"DDInter1847"
] | Deferiprone | Trastuzumab deruxtecan | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Major | 2 | [
[
[
1292,
25,
1363
]
],
[
[
1292,
25,
384
],
[
384,
24,
1363
]
],
[
[
1292,
64,
599
],
[
599,
24,
1363
]
],
[
[
1292,
25,
1259
],
[
1259,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib"... | Deferiprone may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Deferiprone may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause... |
DB01235 | DB08865 | 1,191 | 1,593 | [
"DDInter1054",
"DDInter448"
] | Levodopa | Crizotinib | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1191,
24,
1593
]
],
[
[
1191,
7,
7972
],
[
7972,
46,
1593
]
],
[
[
1191,
18,
1918
],
[
1918,
57,
1593
]
],
[
[
1191,
21,
29093
],
[
29... | [
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Levodopa",
"{u} (Compound) upregulates {v} (Gene)",
"COL11A1"
],
[
"COL11A1",
"{u} (Gene) is upregulated by {v} (C... | Levodopa (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Crizotinib (Compound)
Levodopa (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Crizotinib (Compound)
Levodopa (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
... |
DB00196 | DB00813 | 600 | 704 | [
"DDInter743",
"DDInter722"
] | Fluconazole | Fentanyl | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Major | 2 | [
[
[
600,
25,
704
]
],
[
[
600,
23,
307
],
[
307,
1,
704
]
],
[
[
600,
24,
194
],
[
194,
40,
704
]
],
[
[
600,
24,
543
],
[
543,
1,
... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fentanyl (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fentanyl (Compound)
Fluc... |
DB00968 | DB01088 | 1,551 | 714 | [
"DDInter1185",
"DDInter908"
] | Methyldopa | Iloprost | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1551,
24,
714
]
],
[
[
1551,
63,
1648
],
[
1648,
24,
714
]
],
[
[
1551,
24,
22
],
[
22,
63,
714
]
],
[
[
1551,
25,
1053
],
[
1053,
... | [
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedri... |
DB01394 | DB05679 | 1,554 | 1,683 | [
"DDInter431",
"DDInter1907"
] | Colchicine | Ustekinumab | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1554,
24,
1683
]
],
[
[
1554,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
1554,
24,
309
],
[
309,
24,
1683
]
],
[
[
1554,
25,
478
],
[
478,
... | [
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepil... |
DB01033 | DB08908 | 328 | 713 | [
"DDInter1156",
"DDInter564"
] | Mercaptopurine | Dimethyl fumarate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
328,
24,
713
]
],
[
[
328,
24,
996
],
[
996,
24,
713
]
],
[
[
328,
63,
552
],
[
552,
24,
713
]
],
[
[
328,
24,
270
],
[
270,
63,... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Carm... |
DB00996 | DB11130 | 1,198 | 407 | [
"DDInter791",
"DDInter1344"
] | Gabapentin | Opium | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to tr... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1198,
24,
407
]
],
[
[
1198,
63,
662
],
[
662,
24,
407
]
],
[
[
1198,
24,
849
],
[
849,
24,
407
]
],
[
[
1198,
64,
475
],
[
475,
... | [
[
[
"Gabapentin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Gabapentin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Gabapentin may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Gabapentin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyr... |
DB01320 | DB06772 | 651 | 310 | [
"DDInter783",
"DDInter259"
] | Fosphenytoin | Cabazitaxel | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
651,
24,
310
]
],
[
[
651,
63,
973
],
[
973,
24,
310
]
],
[
[
651,
6,
3486
],
[
3486,
45,
310
]
],
[
[
651,
21,
28892
],
[
28892,
... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Fosphenytoin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Cabazitaxel (Compound)
Fosphenytoin... |
DB00443 | DB01162 | 251 | 195 | [
"DDInter195",
"DDInter1767"
] | Betamethasone | Terazosin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate. | Moderate | 1 | [
[
[
251,
24,
195
]
],
[
[
251,
24,
1205
],
[
1205,
40,
195
]
],
[
[
251,
6,
4973
],
[
4973,
45,
195
]
],
[
[
251,
7,
1996
],
[
1996,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prazosin"
],
[... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Prazosin and Prazosin (Compound) resembles Terazosin (Compound)
Betamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Terazosin (Compound)
Betamethasone (Compound) upregulates CASP2 (Gene) and CASP2 (Gene) i... |
DB01064 | DB01087 | 1,148 | 1,520 | [
"DDInter987",
"DDInter1520"
] | Isoprenaline | Primaquine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
1148,
24,
1520
]
],
[
[
1148,
24,
1487
],
[
1487,
64,
1520
]
],
[
[
1148,
6,
9842
],
[
9842,
45,
1520
]
],
[
[
1148,
21,
28722
],
[
28... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Isoprenaline (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Primaquine (Compound)
Isoprenaline ... |
DB00635 | DB01132 | 1,573 | 1,130 | [
"DDInter1515",
"DDInter1472"
] | Prednisone | Pioglitazone | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1573,
24,
1130
]
],
[
[
1573,
6,
8374
],
[
8374,
45,
1130
]
],
[
[
1573,
21,
28661
],
[
28661,
60,
1130
]
],
[
[
1573,
40,
1103
],
[
1... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Prednisone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Prednisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pioglitazone (Compound)
Prednisone (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Pioglitazone (Compound)
Prednisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause... |
DB01059 | DB09104 | 956 | 286 | [
"DDInter1313",
"DDInter1118"
] | Norfloxacin | Magnesium hydroxide | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
956,
24,
286
]
],
[
[
956,
24,
820
],
[
820,
23,
286
]
],
[
[
956,
23,
60
],
[
60,
23,
286
]
],
[
[
956,
63,
1559
],
[
1559,
23,... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine... |
DB00563 | DB11901 | 663 | 913 | [
"DDInter1174",
"DDInter107"
] | Methotrexate | Apalutamide | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
663,
24,
913
]
],
[
[
663,
24,
110
],
[
110,
62,
913
]
],
[
[
663,
24,
1247
],
[
1247,
23,
913
]
],
[
[
663,
63,
600
],
[
600,
2... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00443 | DB09045 | 251 | 52 | [
"DDInter195",
"DDInter607"
] | Betamethasone | Dulaglutide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
251,
24,
52
]
],
[
[
251,
40,
1103
],
[
1103,
23,
52
]
],
[
[
251,
24,
170
],
[
170,
23,
52
]
],
[
[
251,
24,
609
],
[
609,
24,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that c... |
DB00218 | DB14568 | 1,176 | 982 | [
"DDInter1247",
"DDInter1000"
] | Moxifloxacin | Ivosidenib | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
1176,
25,
982
]
],
[
[
1176,
23,
112
],
[
112,
23,
982
]
],
[
[
1176,
24,
543
],
[
543,
24,
982
]
],
[
[
1176,
23,
147
],
[
147,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and ... |
DB01190 | DB01319 | 568 | 34 | [
"DDInter398",
"DDInter777"
] | Clindamycin | Fosamprenavir | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
568,
24,
34
]
],
[
[
568,
63,
1091
],
[
1091,
40,
34
]
],
[
[
568,
6,
8374
],
[
8374,
45,
34
]
],
[
[
568,
21,
29062
],
[
29062,
... | [
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
... | Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Clindamycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Clindamycin (Compound) causes Neutropenia (Side Effect) an... |
DB00773 | DB15093 | 896 | 1,654 | [
"DDInter702",
"DDInter1698"
] | Etoposide | Somapacitan | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
896,
24,
1654
]
],
[
[
896,
63,
168
],
[
168,
23,
1654
]
],
[
[
896,
63,
10
],
[
10,
24,
1654
]
],
[
[
896,
24,
351
],
[
351,
24... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may ... |
DB00836 | DB00978 | 543 | 739 | [
"DDInter1088",
"DDInter1084"
] | Loperamide | Lomefloxacin | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
543,
24,
739
]
],
[
[
543,
24,
945
],
[
945,
40,
739
]
],
[
[
543,
63,
1176
],
[
1176,
1,
739
]
],
[
[
543,
21,
28921
],
[
28921,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
],
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin... |
DB08899 | DB11652 | 129 | 1,155 | [
"DDInter649",
"DDInter1891"
] | Enzalutamide | Tucatinib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
129,
25,
1155
]
],
[
[
129,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
129,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
129,
24,
659
],
[
659,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarot... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine ... |
DB01105 | DB11732 | 222 | 1,097 | [
"DDInter1665",
"DDInter1027"
] | Sibutramine | Lasmiditan | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Major | 2 | [
[
[
222,
25,
1097
]
],
[
[
222,
63,
701
],
[
701,
24,
1097
]
],
[
[
222,
24,
478
],
[
478,
24,
1097
]
],
[
[
222,
23,
384
],
[
384,
... | [
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lasmiditan"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemasti... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilot... |
DB00295 | DB00514 | 475 | 506 | [
"DDInter1244",
"DDInter527"
] | Morphine | Dextromethorphan | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Moderate | 1 | [
[
[
475,
24,
506
]
],
[
[
475,
40,
197
],
[
197,
40,
506
]
],
[
[
475,
1,
1235
],
[
1235,
40,
506
]
],
[
[
475,
64,
534
],
[
534,
40... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Morphine",
"{u} (Compound) resembles {v} (Compound)",
"Levorphanol"
],
[
"Levorphanol",
"{u} (Compound) rese... | Morphine (Compound) resembles Levorphanol (Compound) and Levorphanol (Compound) resembles Dextromethorphan (Compound)
Morphine (Compound) resembles Hydrocodone (Compound) and Hydrocodone (Compound) resembles Dextromethorphan (Compound)
Morphine may lead to a major life threatening interaction when taken with Tramadol a... |
DB00900 | DB08901 | 45 | 1,468 | [
"DDInter544",
"DDInter1492"
] | Didanosine | Ponatinib | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
45,
24,
1468
]
],
[
[
45,
7,
7245
],
[
7245,
46,
1468
]
],
[
[
45,
6,
4071
],
[
4071,
57,
1468
]
],
[
[
45,
21,
28852
],
[
28852,
... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Didanosine",
"{u} (Compound) upregulates {v} (Gene)",
"SSBP2"
],
[
"SSBP2",
"{u} (Gene) is upregulated by {v} (Co... | Didanosine (Compound) upregulates SSBP2 (Gene) and SSBP2 (Gene) is upregulated by Ponatinib (Compound)
Didanosine (Compound) binds PNP (Gene) and PNP (Gene) is downregulated by Ponatinib (Compound)
Didanosine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Ponatinib (Compound)
Didan... |
DB00569 | DB00975 | 553 | 1,317 | [
"DDInter775",
"DDInter573"
] | Fondaparinux | Dipyridamole | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Major | 2 | [
[
[
553,
25,
1317
]
],
[
[
553,
21,
28748
],
[
28748,
60,
1317
]
],
[
[
553,
23,
1631
],
[
1631,
62,
1317
]
],
[
[
553,
24,
958
],
[
958,
... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dipyridamole"
]
],
[
[
"Fondaparinux",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Co... | Fondaparinux (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Dipyridamole (Compound)
Fondaparinux may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Dipyridamole
... |
DB00881 | DB06691 | 954 | 849 | [
"DDInter1554",
"DDInter1155"
] | Quinapril | Mepyramine | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
954,
24,
849
]
],
[
[
954,
63,
1648
],
[
1648,
24,
849
]
],
[
[
954,
24,
407
],
[
407,
63,
849
]
],
[
[
954,
24,
1376
],
[
1376,
... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may c... |
DB00047 | DB01611 | 176 | 1,487 | [
"DDInter932",
"DDInter893"
] | Insulin glargine | Hydroxychloroquine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
176,
24,
1487
]
],
[
[
176,
24,
1247
],
[
1247,
23,
1487
]
],
[
[
176,
24,
168
],
[
168,
24,
1487
]
],
[
[
176,
63,
521
],
[
521,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfame... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when ta... |
DB00252 | DB00518 | 362 | 510 | [
"DDInter1460",
"DDInter35"
] | Phenytoin | Albendazole | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Moderate | 1 | [
[
[
362,
24,
510
]
],
[
[
362,
24,
1370
],
[
1370,
40,
510
]
],
[
[
362,
6,
4973
],
[
4973,
45,
510
]
],
[
[
362,
7,
10670
],
[
10670,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albendazole"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mebendazole"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Mebendazole and Mebendazole (Compound) resembles Albendazole (Compound)
Phenytoin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Albendazole (Compound)
Phenytoin (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) i... |
DB04845 | DB11979 | 309 | 1,320 | [
"DDInter1001",
"DDInter625"
] | Ixabepilone | Elagolix | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
309,
24,
1320
]
],
[
[
309,
63,
168
],
[
168,
23,
1320
]
],
[
[
309,
63,
1249
],
[
1249,
24,
1320
]
],
[
[
309,
24,
129
],
[
129,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin... |
DB00031 | DB01125 | 20 | 279 | [
"DDInter1764",
"DDInter98"
] | Tenecteplase | Anisindione | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Major | 2 | [
[
[
20,
25,
279
]
],
[
[
20,
24,
1595
],
[
1595,
24,
279
]
],
[
[
20,
24,
557
],
[
557,
63,
279
]
],
[
[
20,
25,
1564
],
[
1564,
64,... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Tenecteplase may cause a moderate interaction that could ... |
DB00641 | DB08816 | 467 | 578 | [
"DDInter1675",
"DDInter1802"
] | Simvastatin | Ticagrelor | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
467,
24,
578
]
],
[
[
467,
5,
11576
],
[
11576,
44,
578
]
],
[
[
467,
6,
4973
],
[
4973,
45,
578
]
],
[
[
467,
21,
28762
],
[
28762,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Simvastatin",
"{u} (Compound) treats {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
... | Simvastatin (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Ticagrelor (Compound)
Simvastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Simvastatin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused... |
DB00635 | DB15091 | 1,573 | 676 | [
"DDInter1515",
"DDInter1901"
] | Prednisone | Upadacitinib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1573,
25,
676
]
],
[
[
1573,
23,
1193
],
[
1193,
23,
676
]
],
[
[
1573,
62,
1461
],
[
1461,
23,
676
]
],
[
[
1573,
24,
1430
],
[
1430,... | [
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc g... | Prednisone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Prednisone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vit... |
DB00622 | DB01222 | 1,081 | 617 | [
"DDInter1287",
"DDInter246"
] | Nicardipine | Budesonide | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1081,
24,
617
]
],
[
[
1081,
63,
251
],
[
251,
1,
617
]
],
[
[
1081,
24,
1220
],
[
1220,
1,
617
]
],
[
[
1081,
6,
8374
],
[
8374,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesoni... |
DB01227 | DB09280 | 1,301 | 1,604 | [
"DDInter1043",
"DDInter1101"
] | Levacetylmethadol | Lumacaftor | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
1301,
25,
1604
]
],
[
[
1301,
64,
593
],
[
593,
24,
1604
]
],
[
[
1301,
25,
1342
],
[
1342,
24,
1604
]
],
[
[
1301,
63,
1347
],
[
1347... | [
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
... | Levacetylmethadol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Levacetylmethadol may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause a m... |
DB00631 | DB14723 | 372 | 159 | [
"DDInter405",
"DDInter1026"
] | Clofarabine | Larotrectinib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
372,
24,
159
]
],
[
[
372,
24,
1412
],
[
1412,
63,
159
]
],
[
[
372,
63,
597
],
[
597,
24,
159
]
],
[
[
372,
24,
975
],
[
975,
2... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB06589 | DB14409 | 1,250 | 1,129 | [
"DDInter1400",
"DDInter867"
] | Pazopanib | Human adenovirus e serotype 4 strain cl-68578 antigen | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1250,
24,
1129
]
],
[
[
1250,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1250,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
1250,
24,
1456
],
[
14... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"E... | Pazopanib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00363 | DB14568 | 695 | 982 | [
"DDInter419",
"DDInter1000"
] | Clozapine | Ivosidenib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
695,
25,
982
]
],
[
[
695,
23,
112
],
[
112,
23,
982
]
],
[
[
695,
64,
168
],
[
168,
23,
982
]
],
[
[
695,
25,
976
],
[
976,
24,... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Clozapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Clozapine may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause ... |
DB00912 | DB04861 | 473 | 1,592 | [
"DDInter1581",
"DDInter1271"
] | Repaglinide | Nebivolol | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
473,
24,
1592
]
],
[
[
473,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
473,
24,
1479
],
[
1479,
23,
1592
]
],
[
[
473,
63,
417
],
[
417,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Repaglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is cause... | Repaglinide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when t... |
DB01234 | DB11627 | 1,220 | 1,367 | [
"DDInter513",
"DDInter860"
] | Dexamethasone | Hepatitis B Vaccine (Recombinant) | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1220,
24,
1367
]
],
[
[
1220,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
1220,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1220,
25,
1019
],
[
10... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Dexamethasone may lead to a major life threatening interaction when taken with Cladr... |
DB09038 | DB11732 | 1,450 | 1,097 | [
"DDInter636",
"DDInter1027"
] | Empagliflozin | Lasmiditan | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1450,
24,
1097
]
],
[
[
1450,
24,
971
],
[
971,
63,
1097
]
],
[
[
1450,
63,
850
],
[
850,
24,
1097
]
],
[
[
1450,
24,
985
],
[
985,
... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab... |
DB08881 | DB12941 | 868 | 466 | [
"DDInter1925",
"DDInter481"
] | Vemurafenib | Darolutamide | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
868,
24,
466
]
],
[
[
868,
64,
1622
],
[
1622,
23,
466
]
],
[
[
868,
63,
34
],
[
34,
23,
466
]
],
[
[
868,
25,
351
],
[
351,
23,... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
],
[
"Vori... | Vemurafenib may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavi... |
DB00261 | DB00420 | 702 | 508 | [
"DDInter93",
"DDInter1532"
] | Anagrelide | Promazine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Major | 2 | [
[
[
702,
25,
508
]
],
[
[
702,
25,
1264
],
[
1264,
63,
508
]
],
[
[
702,
25,
1630
],
[
1630,
1,
508
]
],
[
[
702,
24,
1236
],
[
1236,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promazine"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may caus... | Anagrelide may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promazine
Anagrelide may lead to a major life threatening interaction when taken with Perphenazine and Perphenazine (Compound) resembles Promazi... |
DB00675 | DB15328 | 888 | 829 | [
"DDInter1744",
"DDInter1896"
] | Tamoxifen | Ubrogepant | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
888,
24,
829
]
],
[
[
888,
24,
1476
],
[
1476,
24,
829
]
],
[
[
888,
25,
868
],
[
868,
24,
829
]
],
[
[
888,
63,
1051
],
[
1051,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Tamoxifen may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause ... |
DB00022 | DB01118 | 268 | 33 | [
"DDInter1408",
"DDInter76"
] | Peginterferon alfa-2b | Amiodarone | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
268,
24,
33
]
],
[
[
268,
24,
597
],
[
597,
24,
33
]
],
[
[
268,
24,
1683
],
[
1683,
63,
33
]
],
[
[
268,
63,
491
],
[
491,
24,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlor... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when ... |
DB00574 | DB04896 | 121 | 901 | [
"DDInter717",
"DDInter1220"
] | Fenfluramine | Milnacipran | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Major | 2 | [
[
[
121,
25,
901
]
],
[
[
121,
25,
41
],
[
41,
1,
901
]
],
[
[
121,
64,
1349
],
[
1349,
40,
901
]
],
[
[
121,
63,
13
],
[
13,
24,
... | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran... | Fenfluramine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Milnacipran (Compound)
Fenfluramine m... |
DB00011 | DB00019 | 1,451 | 1,257 | [
"DDInter944",
"DDInter1405"
] | Interferon alfa-n1 | Pegfilgrastim | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Moderate | 1 | [
[
[
1451,
24,
1257
]
],
[
[
1451,
24,
1555
],
[
1555,
63,
1257
]
],
[
[
1451,
63,
491
],
[
491,
24,
1257
]
],
[
[
1451,
25,
1101
],
[
1101... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxalipla... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00877 | DB06636 | 629 | 1,623 | [
"DDInter1678",
"DDInter980"
] | Sirolimus | Isavuconazonium | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
629,
24,
1623
]
],
[
[
629,
24,
222
],
[
222,
23,
1623
]
],
[
[
629,
63,
1601
],
[
1601,
24,
1623
]
],
[
[
629,
24,
1213
],
[
1213,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Lor... |
DB01059 | DB09078 | 956 | 1,228 | [
"DDInter1313",
"DDInter1036"
] | Norfloxacin | Lenvatinib | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
956,
24,
1228
]
],
[
[
956,
62,
112
],
[
112,
23,
1228
]
],
[
[
956,
24,
609
],
[
609,
24,
1228
]
],
[
[
956,
63,
770
],
[
770,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin an... |
DB00175 | DB01229 | 681 | 973 | [
"DDInter1509",
"DDInter1377"
] | Pravastatin | Paclitaxel | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravasta... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
681,
24,
973
]
],
[
[
681,
24,
310
],
[
310,
63,
973
]
],
[
[
681,
6,
7524
],
[
7524,
45,
973
]
],
[
[
681,
21,
29267
],
[
29267,
... | [
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[... | Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Pravastatin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Pravastatin (C... |
DB00631 | DB00740 | 372 | 424 | [
"DDInter405",
"DDInter1596"
] | Clofarabine | Riluzole | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. | Moderate | 1 | [
[
[
372,
24,
424
]
],
[
[
372,
6,
17404
],
[
17404,
45,
424
]
],
[
[
372,
7,
2096
],
[
2096,
57,
424
]
],
[
[
372,
18,
5064
],
[
5064,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riluzole"
]
],
[
[
"Clofarabine",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Clofarabine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Riluzole (Compound)
Clofarabine (Compound) upregulates TERF2IP (Gene) and TERF2IP (Gene) is downregulated by Riluzole (Compound)
Clofarabine (Compound) downregulates PAFAH1B3 (Gene) and PAFAH1B3 (Gene) is downregulated by Riluzole (Compound)
Clofara... |
DB01253 | DB12500 | 628 | 283 | [
"DDInter664",
"DDInter714"
] | Ergometrine | Fedratinib | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
628,
24,
283
]
],
[
[
628,
24,
351
],
[
351,
23,
283
]
],
[
[
628,
63,
1419
],
[
1419,
24,
283
]
],
[
[
628,
24,
951
],
[
951,
2... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib... |
DB00916 | DB04948 | 112 | 1,084 | [
"DDInter1202",
"DDInter1083"
] | Metronidazole | Lofexidine | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Minor | 0 | [
[
[
112,
23,
1084
]
],
[
[
112,
62,
618
],
[
618,
24,
1084
]
],
[
[
112,
23,
774
],
[
774,
63,
1084
]
],
[
[
112,
23,
688
],
[
688,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lofexidine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abarelix"
],
[
... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Degarelix and Degarelix... |
DB01172 | DB09050 | 416 | 931 | [
"DDInter1004",
"DDInter333"
] | Kanamycin | Ceftolozane | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. The manufacturer of this drug is Cubist Pharmac... | Moderate | 1 | [
[
[
416,
24,
931
]
],
[
[
416,
74,
361
],
[
361,
24,
931
]
],
[
[
416,
63,
1096
],
[
1096,
24,
931
]
],
[
[
416,
74,
361
],
[
361,
2... | [
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftolozane"
]
],
[
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken wi... | Kanamycin (Compound) resembles Neomycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Ceftolozane
Kanamycin may cause a moderate interaction that could exacerb... |
DB00370 | DB01362 | 1,251 | 497 | [
"DDInter1230",
"DDInter960"
] | Mirtazapine | Iohexol | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1251,
25,
497
]
],
[
[
1251,
7,
5727
],
[
5727,
46,
497
]
],
[
[
1251,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1251,
24,
530
],
[
530,
... | [
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Mirtazapine",
"{u} (Compound) upregulates {v} (Gene)",
"AGR2"
],
[
"AGR2",
"{u} (Gene) is upregulated by {v} (Compound)",
"... | Mirtazapine (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Iohexol (Compound)
Mirtazapine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00987 | DB01042 | 1,224 | 1,307 | [
"DDInter460",
"DDInter1144"
] | Cytarabine | Melphalan | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
1224,
24,
1307
]
],
[
[
1224,
5,
11555
],
[
11555,
44,
1307
]
],
[
[
1224,
7,
3151
],
[
3151,
46,
1307
]
],
[
[
1224,
23,
956
],
[
956... | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Cytarabine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease... | Cytarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Melphalan (Compound)
Cytarabine (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Melphalan (Compound)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Norf... |
DB00072 | DB01177 | 550 | 77 | [
"DDInter1846",
"DDInter904"
] | Trastuzumab | Idarubicin | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
550,
25,
77
]
],
[
[
550,
24,
496
],
[
496,
63,
77
]
],
[
[
550,
63,
1257
],
[
1257,
24,
77
]
],
[
[
550,
24,
66
],
[
66,
24,
... | [
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with P... |
DB08816 | DB08901 | 578 | 1,468 | [
"DDInter1802",
"DDInter1492"
] | Ticagrelor | Ponatinib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
578,
25,
1468
]
],
[
[
578,
63,
478
],
[
478,
24,
1468
]
],
[
[
578,
6,
4973
],
[
4973,
45,
1468
]
],
[
[
578,
21,
29024
],
[
29024,
... | [
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ticagrelor (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound)
Ticagrelor (Compound) ca... |
DB06779 | DB12500 | 365 | 283 | [
"DDInter470",
"DDInter714"
] | Dalteparin | Fedratinib | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
365,
25,
283
]
],
[
[
365,
64,
885
],
[
885,
24,
283
]
],
[
[
365,
63,
529
],
[
529,
24,
283
]
],
[
[
365,
25,
1618
],
[
1618,
2... | [
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{... | Dalteparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may ... |
DB00734 | DB00836 | 1,664 | 543 | [
"DDInter1605",
"DDInter1088"
] | Risperidone | Loperamide | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
1664,
24,
543
]
],
[
[
1664,
24,
649
],
[
649,
1,
543
]
],
[
[
1664,
24,
262
],
[
262,
24,
543
]
],
[
[
1664,
63,
888
],
[
888,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Loperamide (Compound)
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could... |
DB11952 | DB14723 | 800 | 159 | [
"DDInter612",
"DDInter1026"
] | Duvelisib | Larotrectinib | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
800,
24,
159
]
],
[
[
800,
62,
222
],
[
222,
23,
159
]
],
[
[
800,
23,
466
],
[
466,
23,
159
]
],
[
[
800,
64,
1135
],
[
1135,
2... | [
[
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Duvelisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Duvelisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolut... |
DB00393 | DB08904 | 854 | 375 | [
"DDInter1295",
"DDInter342"
] | Nimodipine | Certolizumab pegol | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
854,
24,
375
]
],
[
[
854,
24,
1593
],
[
1593,
24,
375
]
],
[
[
854,
1,
409
],
[
409,
24,
375
]
],
[
[
854,
63,
58
],
[
58,
24,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Nimodipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction th... |
DB00222 | DB08899 | 245 | 129 | [
"DDInter825",
"DDInter649"
] | Glimepiride | Enzalutamide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
245,
24,
129
]
],
[
[
245,
6,
6017
],
[
6017,
45,
129
]
],
[
[
245,
21,
28703
],
[
28703,
60,
129
]
],
[
[
245,
24,
1247
],
[
1247,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Glimepiride",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compoun... | Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Enzalutamide (Compound)
Glimepiride (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazo... |
DB00939 | DB09135 | 1,338 | 1,211 | [
"DDInter1135",
"DDInter967"
] | Meclofenamic acid | Ioxilan | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
1338,
25,
1211
]
],
[
[
1338,
24,
712
],
[
712,
25,
1211
]
],
[
[
1338,
63,
372
],
[
372,
25,
1211
]
],
[
[
1338,
74,
1512
],
[
1512,
... | [
[
[
"Meclofenamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Ioxilan
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabi... |
DB00220 | DB00682 | 798 | 126 | [
"DDInter1276",
"DDInter1951"
] | Nelfinavir | Warfarin | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
798,
24,
126
]
],
[
[
798,
6,
7950
],
[
7950,
45,
126
]
],
[
[
798,
63,
168
],
[
168,
23,
126
]
],
[
[
798,
24,
135
],
[
135,
62... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Nelfinavir (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Warfarin (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin
Nelfinavir may cause a m... |
DB00468 | DB11915 | 1,424 | 1,293 | [
"DDInter1557",
"DDInter1909"
] | Quinine | Valbenazine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
1424,
24,
1293
]
],
[
[
1424,
23,
112
],
[
112,
23,
1293
]
],
[
[
1424,
24,
710
],
[
710,
63,
1293
]
],
[
[
1424,
63,
521
],
[
521,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimeti... |
DB00593 | DB09054 | 1,464 | 384 | [
"DDInter695",
"DDInter905"
] | Ethosuximide | Idelalisib | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1464,
24,
384
]
],
[
[
1464,
24,
222
],
[
222,
23,
384
]
],
[
[
1464,
63,
58
],
[
58,
24,
384
]
],
[
[
1464,
24,
723
],
[
723,
2... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Ale... |
DB00078 | DB06779 | 1,172 | 365 | [
"DDInter898",
"DDInter470"
] | Ibritumomab tiuxetan | Dalteparin | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
1172,
25,
365
]
],
[
[
1172,
23,
539
],
[
539,
62,
365
]
],
[
[
1172,
24,
1100
],
[
1100,
24,
365
]
],
[
[
1172,
24,
1427
],
[
1427,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
... | Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxi... |
DB00009 | DB00712 | 1,271 | 1,274 | [
"DDInter56",
"DDInter763"
] | Alteplase | Flurbiprofen | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
1271,
24,
1274
]
],
[
[
1271,
24,
935
],
[
935,
63,
1274
]
],
[
[
1271,
23,
297
],
[
297,
62,
1274
]
],
[
[
1271,
24,
529
],
[
529,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Alteplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cau... |
DB00197 | DB01149 | 1,324 | 851 | [
"DDInter1881",
"DDInter1274"
] | Troglitazone | Nefazodone | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
1324,
24,
851
]
],
[
[
1324,
24,
1178
],
[
1178,
1,
851
]
],
[
[
1324,
24,
673
],
[
673,
40,
851
]
],
[
[
1324,
24,
466
],
[
466,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Nefazodone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Nefa... |
DB00745 | DB06595 | 307 | 1,491 | [
"DDInter1236",
"DDInter1214"
] | Modafinil | Midostaurin | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
307,
24,
1491
]
],
[
[
307,
23,
1135
],
[
1135,
62,
1491
]
],
[
[
307,
23,
761
],
[
761,
24,
1491
]
],
[
[
307,
63,
888
],
[
888,
... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Modafinil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin and Saxagliptin ma... |
DB04865 | DB06772 | 4 | 310 | [
"DDInter1335",
"DDInter259"
] | Omacetaxine mepesuccinate | Cabazitaxel | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
4,
24,
310
]
],
[
[
4,
63,
973
],
[
973,
24,
310
]
],
[
[
4,
18,
16974
],
[
16974,
45,
310
]
],
[
[
4,
24,
800
],
[
800,
63,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Omacetaxine mepesuccinate (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is bound by Cab... |
DB08895 | DB16582 | 976 | 899 | [
"DDInter1825",
"DDInter1080"
] | Tofacitinib | Lisocabtagene maraleucel | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has ... | Major | 2 | [
[
[
976,
25,
899
]
],
[
[
976,
64,
869
],
[
869,
24,
899
]
],
[
[
976,
24,
810
],
[
810,
24,
899
]
],
[
[
976,
25,
1362
],
[
1362,
2... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisocabtagene maraleucel"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan"... | Tofacitinib may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lisocabtagene maraleucel
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-... |
DB08880 | DB13874 | 1,510 | 1,501 | [
"DDInter1771",
"DDInter639"
] | Teriflunomide | Enasidenib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
1510,
24,
1501
]
],
[
[
1510,
64,
663
],
[
663,
24,
1501
]
],
[
[
1510,
63,
1149
],
[
1149,
24,
1501
]
],
[
[
1510,
25,
1619
],
[
1619... | [
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Me... | Teriflunomide may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Ezetimibe and Ezetimibe ma... |
DB00704 | DB00744 | 267 | 1,288 | [
"DDInter1263",
"DDInter1962"
] | Naltrexone | Zileuton | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Moderate | 1 | [
[
[
267,
24,
1288
]
],
[
[
267,
21,
29232
],
[
29232,
60,
1288
]
],
[
[
267,
63,
482
],
[
482,
24,
1288
]
],
[
[
267,
24,
187
],
[
187,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused... | Naltrexone (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Zileuton (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
... |
DB00023 | DB09075 | 305 | 498 | [
"DDInter127",
"DDInter621"
] | Asparaginase Escherichia coli | Edoxaban | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Moderate | 1 | [
[
[
305,
24,
498
]
],
[
[
305,
24,
109
],
[
109,
24,
498
]
],
[
[
305,
24,
1496
],
[
1496,
63,
498
]
],
[
[
305,
24,
998
],
[
998,
2... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}"... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases w... |
DB00705 | DB09039 | 441 | 1,670 | [
"DDInter496",
"DDInter629"
] | Delavirdine | Eliglustat | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Major | 2 | [
[
[
441,
25,
1670
]
],
[
[
441,
25,
1135
],
[
1135,
62,
1670
]
],
[
[
441,
24,
1409
],
[
1409,
24,
1670
]
],
[
[
441,
24,
1499
],
[
1499,
... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Delavirdine may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a mode... |
DB09078 | DB12825 | 1,228 | 1,375 | [
"DDInter1036",
"DDInter1032"
] | Lenvatinib | Lefamulin | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
1228,
25,
1375
]
],
[
[
1228,
62,
112
],
[
112,
23,
1375
]
],
[
[
1228,
24,
659
],
[
659,
24,
1375
]
],
[
[
1228,
63,
455
],
[
455,
... | [
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Lenvatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilan... |
DB09241 | DB11130 | 1,629 | 407 | [
"DDInter1186",
"DDInter1344"
] | Methylene blue | Opium | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Major | 2 | [
[
[
1629,
25,
407
]
],
[
[
1629,
63,
1190
],
[
1190,
24,
407
]
],
[
[
1629,
64,
529
],
[
529,
24,
407
]
],
[
[
1629,
25,
180
],
[
180,
... | [
[
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
],
[
"Ketamine"... | Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Ketamine and Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Methylene blue may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause... |
DB00261 | DB05578 | 702 | 330 | [
"DDInter93",
"DDInter1566"
] | Anagrelide | Ramucirumab | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
702,
25,
330
]
],
[
[
702,
24,
41
],
[
41,
63,
330
]
],
[
[
702,
24,
901
],
[
901,
24,
330
]
],
[
[
702,
25,
1100
],
[
1100,
24,... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levo... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Milnacipra... |
DB11979 | DB12010 | 1,320 | 214 | [
"DDInter625",
"DDInter785"
] | Elagolix | Fostamatinib | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1320,
24,
214
]
],
[
[
1320,
63,
976
],
[
976,
24,
214
]
],
[
[
1320,
24,
861
],
[
861,
63,
214
]
],
[
[
1320,
64,
879
],
[
879,
... | [
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
... | Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripret... |
DB00480 | DB08913 | 1,668 | 1,186 | [
"DDInter1035",
"DDInter1561"
] | Lenalidomide | Radium Ra 223 dichloride | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
1668,
24,
1186
]
],
[
[
1668,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
1668,
24,
1491
],
[
1491,
24,
1186
]
],
[
[
1668,
24,
1362
],
[
... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Lenalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Eff... | Lenalidomide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when take... |
DB00593 | DB00877 | 1,464 | 629 | [
"DDInter695",
"DDInter1678"
] | Ethosuximide | Sirolimus | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1464,
24,
629
]
],
[
[
1464,
6,
21998
],
[
21998,
45,
629
]
],
[
[
1464,
7,
7972
],
[
7972,
46,
629
]
],
[
[
1464,
21,
28921
],
[
2892... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Ethosuximide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is boun... | Ethosuximide (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Sirolimus (Compound)
Ethosuximide (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Sirolimus (Compound)
Ethosuximide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Si... |
DB00570 | DB15965 | 147 | 1,330 | [
"DDInter1936",
"DDInter1270"
] | Vinblastine | Naxitamab | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
147,
24,
1330
]
],
[
[
147,
24,
1532
],
[
1532,
24,
1330
]
],
[
[
147,
63,
10
],
[
10,
24,
1330
]
],
[
[
147,
25,
770
],
[
770,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone ... |
DB00801 | DB04868 | 1,563 | 478 | [
"DDInter850",
"DDInter1293"
] | Halazepam | Nilotinib | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1563,
24,
478
]
],
[
[
1563,
40,
1565
],
[
1565,
24,
478
]
],
[
[
1563,
24,
629
],
[
629,
24,
478
]
],
[
[
1563,
63,
752
],
[
752,
... | [
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Halazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
],
[
"Clonazepam",
"{u} may cause a moderate i... | Halazepam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exac... |
DB00015 | DB00519 | 582 | 1,638 | [
"DDInter1585",
"DDInter1843"
] | Reteplase | Trandolapril | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Moderate | 1 | [
[
[
582,
24,
1638
]
],
[
[
582,
24,
954
],
[
954,
40,
1638
]
],
[
[
582,
24,
714
],
[
714,
63,
1638
]
],
[
[
582,
24,
1061
],
[
1061,
... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Trandolapril (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exace... |
DB11689 | DB11979 | 321 | 1,320 | [
"DDInter1659",
"DDInter625"
] | Selumetinib | Elagolix | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
321,
24,
1320
]
],
[
[
321,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
321,
64,
129
],
[
129,
24,
1320
]
],
[
[
321,
25,
913
],
[
913,
... | [
[
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Selumetinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide ma... |
DB00850 | DB01168 | 1,630 | 1,053 | [
"DDInter1432",
"DDInter1526"
] | Perphenazine | Procarbazine | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1630,
24,
1053
]
],
[
[
1630,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1630,
24,
480
],
[
480,
24,
1053
]
],
[
[
1630,
1,
9
],
[
9,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Perphenazine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is ... | Perphenazine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Pro... |
DB01165 | DB06589 | 1,539 | 1,250 | [
"DDInter1325",
"DDInter1400"
] | Ofloxacin | Pazopanib | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1539,
24,
1250
]
],
[
[
1539,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
1539,
7,
17450
],
[
17450,
46,
1250
]
],
[
[
1539,
18,
5245
],
[
52... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Ofloxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Ofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Ofloxacin (Compound) upregulates FKBP14 (Gene) and FKBP14 (Gene) is upregulated by Pazopanib (Compound)
Ofloxacin (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Pazopanib (Compound)
Ofloxacin (Compo... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.